News >

Treatments Emerging to Combat Endocrine Resistance in ER+ Breast Cancer

Danielle Bucco
Published: Friday, Apr 06, 2018

Heather Han, MD

Heather Han, MD
Most patients with ER-positive breast cancer will develop resistance to treatment with endocrine therapy, said Heather Han, MD, which makes understanding causes of resistance an important area of study.

on Breast Cancer, Han, research director, medical oncologist, Department of Breast Oncology, Moffitt Cancer Center, discussed emerging approaches for combating endocrine resistance in patients with ER-positive breast cancer.

OncLive: Please provide an overview of your presentation on ER-positive breast cancer.

Han: In my presentation, I discussed hormone therapy and the main mechanisms of endocrine resistance. HR-positive breast cancer is the most common subtype of breast cancer. The main treatment is endocrine therapy, but unfortunately resistance is universal to endocrine therapies. Patients end up having recurrence and progressive disease. Understanding the mechanism of endocrine resistance is critical in order for us to find targeted therapy to try and overcome the resistance.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: PARP Inhibition in Breast Cancer: Practical Methods to Interpret and Apply the Evidence for Your PatientsAug 30, 20191.5
Provider and Caregiver Connection™: Addressing Patient Concerns in the Management of Premenopausal Breast CancerAug 31, 20192.0
Publication Bottom Border
Border Publication